Rani Therapeutics (RANI) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($248.4 million vs $111.3 million), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RANI | VCRE |
|---|---|---|
| Share price | $0.792 | $8.82 |
| Market cap | $111.29M | $248.41M |
| 1-day change | -2.48% | +1.85% |
| YTD return | -39.84% | — |
| 1-year return | +62.42% | — |
| 5-year return | -95.88% | — |
| EPS (TTM) | $-0.15 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.87 | $17.80 |
| 52-week low | $0.445 | $7.88 |
| Distance from 52-week high | -79.53% | -50.45% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +275.96% |
| Average volume | 746.05K | 16.24K |
| Shares outstanding | 115.42M | 28.16M |
| Employees | — | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Vicore Pharma AB is about 2.2 times larger than Rani Therapeutics by market value ($248.41M vs $111.29M).
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
RANI vs VCRE FAQ
Which is bigger, Rani Therapeutics or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $248.41M compared with $111.29M for Rani Therapeutics (RANI).
Are Rani Therapeutics and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.